

Published by  
Ministry of Health, Labour and Welfare



Translated by  
Pharmaceuticals and Medical Devices Agency



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of Precautions

## Hydroxychloroquine sulfate

August 30, 2022

### **Therapeutic category**

Agents affecting metabolism, n.e.c. (not elsewhere classified)

### **Non-proprietary name**

Hydroxychloroquine sulfate

### **Safety measure**

Precautions should be revised.

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0611-1 by the Director of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions): Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (N/A)	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Hepatic impairment</u> <u>Hepatic impairment accompanied by increased levels of AST, ALT and <math>\gamma</math>-GTP, etc. may occur.</u>

(N/A) Not Applicable. No corresponding language is included in the current Precautions.